专题：Chronic Lymphocytic Leukemia Research

This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenström macroglobulinemia.
最新文献
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

review Full Text OpenAlex

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

article Full Text OpenAlex

Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion

article Full Text OpenAlex

Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial

article Full Text OpenAlex

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium

article Full Text OpenAlex

Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)

article Full Text OpenAlex

STAT4 gene polymorphisms in human diseases

review Full Text OpenAlex

Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells

article Full Text OpenAlex

High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics

article Full Text OpenAlex

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis

review Full Text OpenAlex

近5年高被引文献
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

review Full Text OpenAlex 3136 FWCI649.38936651

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

article Full Text OpenAlex 2161 FWCI322.65752968

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

article Full Text OpenAlex 1543 FWCI106.92812346

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

article Full Text OpenAlex 1268 FWCI261.57975759

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

review Full Text OpenAlex 1137 FWCI198.73297801

Diffuse Large B-Cell Lymphoma

review Full Text OpenAlex 946 FWCI126.2197953

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

review Full Text OpenAlex 923 FWCI140.6278866

KRAS mutation: from undruggable to druggable in cancer

review Full Text OpenAlex 895 FWCI61.11676076

Management of Rheumatoid Arthritis: An Overview

review Full Text OpenAlex 860 FWCI125.25377681

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

article Full Text OpenAlex 699 FWCI350.59997933